Compare PSTG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTG | BIIB |
|---|---|---|
| Founded | 2009 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 27.3B |
| IPO Year | 2015 | 1996 |
| Metric | PSTG | BIIB |
|---|---|---|
| Price | $67.30 | $183.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 27 |
| Target Price | $90.05 | ★ $202.92 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.42 | N/A |
| EPS | 0.55 | ★ 8.79 |
| Revenue | $3,662,843,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $15.70 | N/A |
| P/E Ratio | $123.45 | ★ $21.37 |
| Revenue Growth | ★ 15.61 | 2.22 |
| 52 Week Low | $43.51 | $115.28 |
| 52 Week High | $100.59 | $202.41 |
| Indicator | PSTG | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 51.75 |
| Support Level | $64.57 | $181.24 |
| Resistance Level | $76.63 | $184.16 |
| Average True Range (ATR) | 2.80 | 4.52 |
| MACD | 0.86 | 1.26 |
| Stochastic Oscillator | 100.00 | 61.34 |
Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).